NasdaqGM - Nasdaq Real Time Price USD

Vera Therapeutics, Inc. (VERA)

21.59

+0.09

+(0.42%)

At close: April 15 at 4:00:00 PM EDT

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units (RSUs) for 105,125 shares of Class A common stock to sixteen (16) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new emplo

GlobeNewswire 6 days ago

VERA
+0.42%
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN). ORIGIN 3 follows the long-term results from the ORIGIN Phase 2b trial, which demonstrated sustained and substantial reductions in Gd-IgA1, hematuria, and proteinuria and showed stabilized kidney function through 96 weeks. The company anticipates the 36-week primary efficacy endpoint data from the

Benzinga 6 days ago

VERA
+0.42%
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial

GlobeNewswire 12 days ago

VERA
+0.42%
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference, which is taking place in Boston, MA from March 3 – 5, 2025. The management team will also participate in on

GlobeNewswire last month

VERA
+0.42%
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned in 2H 2025Expanded atacicept clinical development program in multiple autoimmune kidney diseases proceeding in 2025Strengthened balance sheet to support clinical pipeline development, planned FDA submission, and potential 2026 commercial launch of atacicept for the treatment of IgAN BRISBANE, Calif.,

GlobeNewswire last month

VERA
+0.42%
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. “This

GlobeNewswire 2 months ago

VERA
+0.42%
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 – 16, 2025. The management team will also participate in one-on-one i

GlobeNewswire 3 months ago

VERA
+0.42%
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. “We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in th

GlobeNewswire 4 months ago

VERA
+0.42%
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet

The consensus price target hints at a 27.3% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 5 months ago

VERA
+0.42%
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands the investigation of atacicept into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition; BRISBANE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on

GlobeNewswire 5 months ago

VERA
+0.42%
Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside Chat and

GlobeNewswire 5 months ago

VERA
+0.42%
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 with simultaneous peer-reviewed publication in the Journal of the American Society of Nephrology (JASN)Completed enrollment of the primary endpoint cohort in the pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN; topline data expected in Q2 2025Announced expanded atacicept development

GlobeNewswire 5 months ago

VERA
+0.42%
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A common stock at a price to the public of $42.00 per share. The gross proceeds to Vera from the offering, before deducting underwriting discounts and commiss

GlobeNewswire 5 months ago

VERA
+0.42%
Vera Therapeutics price target raised to $64 from $56 at Guggenheim

Guggenheim raised the firm’s price target on Vera Therapeutics (VERA) to $64 from $56 and keeps a Buy rating on the shares. After attending the American Society of Nephrology meeting this weekend, the firm says it “once again came away impressed” with the clinical profile for Vera’s atacicept in the treatment of immunoglobulin A nephropathy, or IgAN. Following the ASN meeting, the firm increased its atacicept probability of success view to 85% from 80% and its market penetration rates for the AP

TipRanks 5 months ago

VERA
+0.42%
Vera Therapeutics Breaks Out On Promising Results For Kidney Drug

Vera stock catapulted and broke out on Monday after unveiling promising results for its kidney disease treatment.

Investor's Business Daily 5 months ago

VERA
+0.42%
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300.0 million of shares of its Class A common stock. All of the shares are being offered by Vera. In connection with the proposed offering

GlobeNewswire 5 months ago

VERA
+0.42%
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

On Saturday, Vera Therapeutics Inc. (NASDAQ:VERA) released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks of long-term follow-up. These data were presented in a late-breaking oral presentation at the American Society of Nephrology Kidney Week 2024 and published in a manuscript in the Journal of the American Society of Nephrology. Over 96 weeks, participants treated with atacicept demonstrated a -66

Benzinga 5 months ago

VERA
+0.42%
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN Phase 2b study were simultaneously published in the Journal of the American Society of Nephrology;Company will host an investor call and webcast on Monday October 28 at 8:00 AM ET BRISBANE, Calif., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biot

GlobeNewswire 5 months ago

VERA
+0.42%
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Two informational posters for ORIGIN Phase 3 and ORIGIN Extend trials of atacicept in IgAN accepted for presentation at Kidney Week;In-person and virtual R&D Day to discuss expanded atacicept R&D activities scheduled to take place in New York on October 2; BRISBANE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological

GlobeNewswire 6 months ago

VERA
+0.42%
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

PIONEER study expands the investigation of atacicept into a broad definition of IgA nephropathy and into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition;Multiple regulatory and clinical milestones expected over the next 18 months; Announcements made at Vera’s R&D Day in New York, where the company’s management team was joined by academic leaders Jonathan Barratt, Richard Lafayette, and Brad Rovin BRISBANE, Calif., Oct. 02, 2024

GlobeNewswire 6 months ago

VERA
+0.42%

Performance Overview

Return	VERA	S&P 500 (^GSPC)
YTD	-48.95%	-8.25%
1-Year	-53.60%	+6.61%
3-Year	-6.62%	+22.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vera Therapeutics, Inc. (VERA)

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics price target raised to $64 from $56 at Guggenheim

Vera Therapeutics Breaks Out On Promising Results For Kidney Drug

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Performance Overview